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Sir,
The recent article by Montgomery et al (2007) has raised yet
again the controversies regarding optimum duration and method
of breast cancer follow-up. In fact, there has been little enthusiasm
in adopting the 2002 National Institute for Clinical Excellence
guidelines. The authors correctly questioned the basic assumptions
behind these guidelines but also agreed that clinical reviews were
ineffective in their analysis. It was also stated that clinically
detected cancers had worse outcomes. With regards to this
particular point, we propose an alternative analysis and inter-
pretation of the data presented. We feel without this clarification,
some patients may be discharged on such an assumption.
Figures 4 and 5 of the above mentioned article included only 48
out of 110 regional relapses, yet the authors did not explain why
isolated contralateral recurrences were excluded. Additionally,
when comparing these 48 cases with Table 3 of the same article, it
was evident that ipsilateral axillary recurrences were also excluded
without justification. This is statistically incorrect as only 4 out of
the 25 pure ipsilateral axillary recurrences were evident on
mammography, thus obscuring any potential benefit of clinical
examination.
To re-analyse the published data, we reproduced an approxima-
tion of Figure 4 using information contained in the original
analysis, see Figure 1:
First, we question the validity of any statistics proposed on small
subsets – note only four cases were included in the ‘clinically
detected’ group. Perhaps, a more relevant analysis would be to
group all palpable cancers since these are equally ‘clinically’
detectable. By performing this analysis, the statistical significance
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Figure 1 Reproduced survival curves using information from the original
paper. Curves are approximates for patients with ipsilateral breast relapse.
Patients with pure axillary disease were excluded.
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Figure 2 Our interpretation of Figure 1 after reclassifying groups into
palpable vs mammographically detected cancers.
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www.bjcancer.combetween mammography and palpable tumours is lost (log rank
P¼0.135), Figure 2, with no difference in outcome. We were not
able to reproduce a full analysis using lymph node detection as
follow-up times were not included in the paper.
Second, the authors did not specify their definition of
survival, that is, breast specific or overall survival, thus
compounding the difficulties in data interpretation. This is
particularly relevant in small groups and represents a strong
confounding factor.
We appreciate the need to improve clinic efficiency but the
evidence presented in this paper does not lead us to agree with the
authors’ conclusion that relapses diagnosed clinically are in
general associated with poorer outcomes and does not take the
argument against clinical follow-up any further.
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